Arabic Arabic English English French French German German
dark

Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02

Evaxion Biotech A/S, a clinical-stage biotech company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced results from both its Phase 1/2a trial of cancer immunotherapy EVX-01 in metastatic melanoma and interim Phase 1/2a trial of cancer immunotherapy EVX-02 in adjuvant melanoma. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Treadmill exercise alleviates neuronal damage by suppressing NLRP3 inflammasome and microglial activation.

Next Post

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)

Related Posts
Total
0
Share